Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 23,545

Document Document Title
WO/2019/176866A1
Provided is a low-molecular weight bispecific polypeptide. A heterodimer uteroglobin is prepared by modifying, to a low-molecular weight uteroglobin, an Fc region in a bispecific antibody constructed from a natural antibody, and causing ...  
WO/2019/174633A1
Provided is a fluorescent probe, containing a) a response polypeptide and b) an optical active polypeptide, wherein the optical active polypeptide is inserted into the response polypeptide. Also provided is a nucleic acid sequence coding...  
WO/2019/173903A1
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and an EGFR antibody such as cetuximab. The anti-cancer effect of cetuximab is enhanced in the presence of SIRPαFc. Specific combinations in...  
WO/2019/178604A1
The present application relates to an isolated chimeric molecule comprising a degradation domain comprising an E3 ubiquitin ligase (E3) motif and a targeting domain capable of specifically directing the degradation domain to a substrate,...  
WO/2019/177138A1
Disclosed is a modified antibody fragment consisting of an antibody fragment capable of binding to misfolded TDP-43 and a chaperone-mediated autophagy transit signal peptide, wherein: the antibody fragment includes a heavy-chain variable...  
WO/2019/173902A1
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRPαFc is enhanced in the presence of daratumumab. Specific combinations...  
WO/2019/175428A1
The present invention relates to engineered cells that enable exosome-mediated delivery of therapeutic cargoes, in particular protein therapeutics and RNA therapeutics. The present invention also relates to inventive polynucleotides, pol...  
WO/2019/178573A1
Truncated, variant, or mutated peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for truncat...  
WO/2019/173837A1
The present disclosure provides dimeric antigen receptors (DAR) constructs comprising a heavy chain binding region on one polypeptide chain and a light chain binding region on a separate polypeptide chain. The two polypeptide chains that...  
WO/2019/173462A1
Nucleic acid molecules are provided herein that can be used, for example, to treat cancer or infections, or to induce an immune response in a subject, or to deliver or express a target molecule in or from a cell.  
WO/2019/172400A1
The purpose of the present invention is to provide a fungus-derived FADGDH that has a direct electron transfer capability. Provided is a fusion protein comprising a fungus-derived FADGDH or mutant thereof and a cytochrome molecule connec...  
WO/2019/170147A1
Provided in the present invention are a composition of immune effector cells and a treatment kit including the composition of immune effector cells, wherein the composition of immune effector cells comprises an initial dose of immune eff...  
WO/2019/169448A1
The present invention relates to antigen binding sites, compositions and uses thereof in the treatment of conditions associated with pathogenic proteins. The present invention provides an antigen binding site that binds to or specificall...  
WO/2019/173832A2
Provided herein are cytokine muteins and cytokine prodrugs and methods of making and using thereof.  
WO/2019/173463A1
Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines...  
WO/2019/169689A1
Provided are an alkaline pectinase mutant and a preparation method therefor. The enzyme mutant is obtained from a library of functional polypeptides constructed on the basis of SAPs.  
WO/2019/173334A1
The invention represents a solution for major unmet medical need in the field of ophthalmology. Accordingly, the invention provides compositions, e.g., an engineered Vascular endothelial growth factor (VEGF) chimeric polypeptide, compris...  
WO/2019/173829A1
Disclosed herein are fusion proteins for use in treating an inflammatory or immune disorder and methods of use. In some examples, the fusion proteins include an anchor domain and a therapeutic polypeptide. In some examples, the fusion pr...  
WO/2019/172605A1
Disclosed are a method for preparing a biomaterial having selectively functionalized tyrosine, a biomaterial having selectively functionalized tyrosine, and a pharmaceutical composition containing same as an active ingredient. The method...  
WO/2019/167962A1
A bispecific antibody having dual antigen specificity for a first antigen and a second antigen, characterized by comprising, in any order, heavy chain variable region and light chain variable region sequences derived from an antibody to ...  
WO/2018/200586A9
The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs.  
WO/2019/161528A1
Provided are antibodies or antigen-binding fragments specific for CD44V6 or v9 epitope which comprises or consists essentially of SEQ ID NO:19 or 43. Also provided are antibody-drug-conjugate (ADC), other derivatives comprising the antib...  
WO/2019/163871A1
The present invention provides a prospective means for use in a novel drug delivery system (DDS), an electronic device production, etc. More particularly, the present invention provides: a fusion protein containing (a) a ferritin monomer...  
WO/2019/165215A1
The present invention relates to compositions and methods comprising a T cell genetically modified to express a CAR and a SMAC mimetic for treating a patient having a disease, a disorder or a condition associated with an elevated express...  
WO/2019/164821A1
Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.  
WO/2019/161684A1
Provided by the present invention is a recombinant protein or the derivative thereof. Said recombinant protein has the amino acid sequence of the N-terminal part of CC chemokine receptor 4 (CCR4). Also provided in the present invention i...  
WO/2019/161796A1
The present application provides a chimeric antigen receptor and application thereof. The chimeric antigen receptor comprises an antigen-binding domain, a transmembrane domain, a costimulatory signal transduction region, a CD3ζ signal t...  
WO/2019/162937A1
The present invention provides compositions and methods for inducing allogenic tumor rejection and, more particularly, but not exclusively, compositions and methods employing fusion proteins comprising an MHC class 1 HLA amino acid seque...  
WO/2019/165233A1
Disclosed herein are antibodies that specifically bind to LRIG1 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting B cell or Natural Killer cell proliferation wit...  
WO/2019/162682A1
The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the mu...  
WO/2019/164970A1
This disclosure relates to HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth. In certain embodiments, this disclosure relates to detecting an HPV protein in a sample and correlating the presence as an indicat...  
WO/2019/165105A1
Ligands of the urokinase receptor and methods of treating, detecting, and imaging cancer with such ligands are disclosed. In particular, the invention relates to a ligand comprising a fusion protein comprising a growth factor domain (GFD...  
WO/2019/161783A1
Provided are fusion proteins that include an apolipoprotein B mRNA editing enzyme catalytic subunit 3A (APOBEC3A) and a clustered regularly interspaced short palindromic repeats (CRISPR) -associated (Cas) protein, optionally further with...  
WO/2019/159934A1
Provided are a fusion protein for measuring the quantity or quality of modified HDL, the fusion protein being a lipid-free standard having good long-term storability, and a method for accurately, reproducibly, and reliably measuring high...  
WO/2019/157691A1
The present invention provides a recombinant chimeric antigen receptor (CAR) gene, a vector comprising same, a CAR-T cell and use thereof. The recombinant CAR gene comprises a nucleic acid sequence encoding the following portions: an ant...  
WO/2019/159084A1
Described herein are methods to affect binding by a multivalent binding molecule to a FZD receptor and a Wnt co-receptor on a cell wherein binding by the multivalent binding molecule to both FZD receptor and co-receptor on the cell activ...  
WO/2019/160099A1
Provided is a peptide which comprises 10-45 amino acids containing: an amino acid sequence KILQQSRIVQX (wherein X is nil or represents S); an amino acid sequence consisting of 10 or more consecutive amino acids in an amino acid sequence ...  
WO/2019/147979A3
Provided herein are compositions including peptide or nucleic acids encoding peptides and related methods for the treatment of angiogenic conditions such as cancer, vascular disorders such as cardiovascular disorders, and infectious dise...  
WO/2019/154313A1
An isolated CD19-binding chimeric antigen receptor, a CRISPR-Cas9 system-based method for knocking out TRAC, B2M and PD-1 genes in T cells in vitro, crRNA used in the method, gene knockout T cells obtained according to the method, and a ...  
WO/2019/156566A1
The invention provides a recombinant bispecific protein, comprising an extracellular domain of a gamma-delta T-cell receptor (TCR) which is fused to a T- cell- and/or Natural Killer (NK) cell-binding domain. The invention further provide...  
WO/2019/153827A1
A method for preparing a liraglutide intermediate polypeptide GLP-1(7-37), comprising: constructing a recombinant liraglutide engineered bacteria, expressing a liraglutide intermediate fusion protein in the form of an inclusion body by m...  
WO/2019/153851A1
A fusion protein, a kit and a CHIP-seq detection method. The fusion protein comprises a Tn5 transposase and an Fc binding protein. The kit comprises said fusion protein and other auxiliary detection reagents. Said method uses said fusion...  
WO/2019/157355A1
The present disclosure provides methods, kits, and compositions for direct immunohistochemical (IHC) staining and direct immunocytochemistiy (ICC) techniques, including applications to multiplex assays, chemically stained samples, and cy...  
WO/2019/154230A1
Provided is a recombinant protein comprising a TRAIL domain and an IgG binding domain IgBD. In the recombinant protein, IgBD can be fused at the N-terminus or C-terminus of the TRAIL domain. The anti-tumor effect of the recombinant prote...  
WO/2019/157131A1
The disclosure relates to cell-permeable stabilized peptide modules and methods of use for e.g., cellular delivery of cargoes.  
WO/2019/154391A1
Provided are a chimeric antigen receptor, a NKG2D CAR-NK cell expressing the chimeric antigen receptor, a preparation method therefor and the use thereof. The chimeric antigen receptor comprises an antigen binding domain, a transmembrane...  
WO/2019/154189A1
A fibroblast growth factor 21 (FGF21) variant, further to a FGF21 variant fusion protein, a protein multimer, and use thereof are provided. The FGF21 variant, fusion protein and protein multimer can significantly improve the binding abil...  
WO/2019/157533A1
The invention provides methods and compositions for use in treating cancer, which advantageously may be achieved by targeting of a tumor microenvironment. The invention provides chimeric antigen receptors (CARs) that target a tumor micro...  
WO/2019/157496A1
Provided are materials and methods for generating chimeric antigen receptors (CARs) specific for human factor VIII (huF.VIII), which huF.VIII CARs are expressed in regulatory T cells and used to treat inhibitor formation in hemophilia A ...  
WO/2019/151320A1
The problem addressed by the present invention is to provide a technique for improving the anticancer effect of ubenimex, especially the anticancer effect on solid cancers. The problem is solved by a compound containing a chain-form stru...  

Matches 1 - 50 out of 23,545